A decrease in PPD specific CD4 T cell CD38 and HLA-DR expression in pulmonary tuberculosis patients after 8 weeks of...

Area of Science:

• Immunology
• Infectious Diseases
• Public Health

Background:

• Tuberculosis (TB) poses a significant global health challenge, particularly in Indonesia.
• The adaptive immune response, mediated by CD4 T cells, is crucial for controlling Mycobacterium tuberculosis (MTB) infection.

Purpose of the Study:

• To investigate the early effects of standard TB therapy on CD4 T cells.
• To identify potential immune markers for assessing TB treatment efficacy.

Main Methods:

• Blood samples were collected from TB patients before and after 8 weeks of treatment.
• MTB-specific CD4 T cells were analyzed ex vivo using PPD stimulation.
• Flow cytometry was employed to measure intracellular cytokines and surface markers (CD38, HLA-DR).

Main Results:

• No significant difference was observed in the total number of PPD-specific CD4 T cells between pre-treatment and post-treatment groups.
• A significant decrease in the proportion of CD38+HLA-DR+ PPD-specific CD4 T cells was found in patients who became smear-negative after treatment.
• This reduction was not specific to Interferon gamma (IFNg), Interleukin-2 (IL-2), or Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) producing cells.

Conclusions:

• Anti-TB treatment alters the adaptive immune response in a measurable way.
• The decrease in the CD38+HLA-DR+ PPD-specific CD4 T cell phenotype may serve as a valuable indicator of successful TB treatment.